Tetanus immune globulin
Tetanus immune globulin is an unknown pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
Trade Name
FDA
EMA
Baytet, hypertet
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| hypertet | Biologic Licensing Application | 2010-10-28 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| tetanus | EFO_0005593 | D013742 | A35 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
Code | Description |
|---|---|
| J1670 | Injection, tetanus immune globulin, human, up to 250 units |
Clinical
Clinical Trials
50 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tetanus | D013742 | EFO_0005593 | A35 | 3 | 3 | 9 | 2 | 2 | 18 |
| Diphtheria | D004165 | EFO_0005549 | A36 | 1 | 1 | 7 | 1 | 1 | 11 |
| Tetany | D013746 | HP_0001281 | P71.3 | 2 | 2 | 2 | 1 | 1 | 7 |
| Poliomyelitis | D011051 | EFO_0007450 | A80 | — | — | 4 | 1 | 1 | 6 |
| Human influenza | D007251 | EFO_0007328 | J11.1 | — | — | 3 | 1 | — | 4 |
| Primary immunodeficiency diseases | D000081207 | — | — | — | — | — | 1 | 1 | 2 |
| Immune system diseases | D007154 | — | D89.9 | — | — | — | 1 | — | 1 |
| Immunologic deficiency syndromes | D007153 | HP_0002721 | D84.9 | — | — | — | 1 | — | 1 |
| Kidney transplantation | D016030 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Whooping cough | D014917 | EFO_0000650 | A37.0 | 2 | — | 6 | — | 4 | 12 |
| Hepatitis b | D006509 | — | — | — | — | 6 | — | 1 | 7 |
| Hepatitis | D006505 | HP_0012115 | K75.9 | — | — | 6 | — | 1 | 7 |
| Meningitis | D008581 | HP_0001287 | G03 | — | 1 | 2 | — | — | 2 |
| Haemophilus infections | D006192 | EFO_1001127 | — | — | — | 2 | — | — | 2 |
| Meningococcal infections | D008589 | EFO_0004249 | A39 | — | — | 2 | — | — | 2 |
| Haemophilus influenzae type b | D019741 | — | — | — | — | 2 | — | — | 2 |
| Epiglottitis | D004826 | EFO_0007261 | J05.10 | — | — | 1 | — | — | 1 |
| Meningococcal meningitis | D008585 | EFO_1001040 | A39.0 | — | 1 | 1 | — | — | 1 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | — | — | 1 | — | — | 1 |
Show 1 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 2 | 1 | — | — | — | 2 |
| Glioblastoma | D005909 | EFO_0000515 | — | 1 | 1 | — | — | — | 2 |
| Glioma | D005910 | EFO_0000520 | — | 1 | 1 | — | — | — | 1 |
| Diffuse intrinsic pontine glioma | D000080443 | — | — | 1 | 1 | — | — | — | 1 |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | 1 | — | — | — | 1 |
| Eczema | D004485 | HP_0000964 | L30.9 | — | 1 | — | — | — | 1 |
| Dermatitis | D003872 | HP_0011123 | L30.9 | — | 1 | — | — | — | 1 |
| Fever | D005334 | HP_0001945 | R50.9 | — | 1 | — | — | — | 1 |
| Typhoid fever | D014435 | EFO_0006789 | A01.0 | — | 1 | — | — | — | 1 |
| Diphtheria-tetanus-acellular pertussis vaccines | D022681 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 1 | — | — | — | — | 1 |
| Arthritis | D001168 | HP_0001369 | M05-M14 | 1 | — | — | — | — | 1 |
| Pregnancy rate | D018873 | — | — | 1 | — | — | — | — | 1 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | — | 1 |
| Clostridium tetani | D003017 | NCBITaxon_1513 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | — | — | — | — | 2 | 2 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | — | — | 2 | 2 |
| Agammaglobulinemia | D000361 | HP_0004313 | D80.1 | — | — | — | — | 1 | 1 |
| Common variable immunodeficiency | D017074 | EFO_0000367 | D83 | — | — | — | — | 1 | 1 |
| Vitamin a deficiency | D014802 | EFO_1001237 | E50 | — | — | — | — | 1 | 1 |
| Night blindness | D009755 | — | H53.6 | — | — | — | — | 1 | 1 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | — | — | — | 1 | 1 |
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | — | — | — | — | 1 | 1 |
| Sclerosis | D012598 | — | — | — | — | — | — | 1 | 1 |
| Communicable diseases | D003141 | — | — | — | — | — | — | 1 | 1 |
Show 9 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tetanus immune globulin |
| INN | — |
| Description | Anti-tetanus immunoglobulin, also known as tetanus immune globulin (TIG) and tetanus antitoxin, is a medication made up of antibodies against the tetanus toxin. It is used to prevent tetanus in those who have a wound that is at high risk and have not been fully vaccinated with tetanus toxoid. It is also used to treat tetanus along with antibiotics and muscle relaxants. It is given by injection into a muscle.
|
| Classification | Protein |
| Drug class | antineoplastics (mitotic inhibitors; tubulin binders) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201582 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 536 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
74 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use